Indication
Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Loading your page…
Loading your page…
Angioedemas, Hereditary
Marketing Authorisation Holder: Takeda Pharmaceuticals International AG
EMA Authorisation: 11/07/2008
INN: icatibant
AI Drug & Interaction Analysis
Free account required
Ask Osler about Firazyr: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.